+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Hand Eczema Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4790893
  • Drug Pipelines
  • 178 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Asana BioSciences
  • Basilea Pharmaceuticals
  • LEO Pharma
  • MORE
‘Chronic Hand Eczema (CHE) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chronic Hand Eczema in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic Hand Eczema from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Chronic Hand Eczema (CHE) - Disease Understanding and Treatment Algorithm

The Chronic Hand Eczema (CHE) market report gives the thorough understanding of the Chronic Hand Eczema by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Chronic Hand Eczema in the US, Europe, and Japan

Chronic Hand Eczema Epidemiology

The Chronic Hand Eczema (CHE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {Total prevalent cases, gender-specific cases, diagnosed cases, severity-specific diagnosed prevalent cases [mild to moderate, moderate, moderate to severe, severe], subgroup-specific diagnosed prevalent cases [Irritant contact eczema, Atopic hand eczema, Allergic contact eczema, Dishydrotic hand eczema, Hyperkeratotic rhagadiform hand eczema, Fingertip eczema] and age-specific diagnosed prevalent cases [20-29 yrs., 30-49 yrs., 50-69 yrs., 70 and above]} scenario of Chronic Hand Eczema in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028

According to this research, total prevalent population of Chronic Hand Eczema (CHE) in 7 major markets was found to be 4,229,215 in 2017

Chronic Hand Eczema Drug Chapters

This segment of the Chronic Hand Eczema report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases

At present, the therapeutic market size of Chronic Hand Eczema is includes topical corticosteroids, calcineurin inhibitors, phototherapy and other radiation therapies. For the relapse or recurrent conditions, systemic therapies are the only available option. These includes short-term oral corticosteroids, immunosuppressant such as azathioprine, methotrexate, cyclosporine, mycophenolate mofetil and oral retinoids. There is no approved systemic therapy available in the US and Japan for the treatment of corticosteroid resistant CHE. However, alitretinoin is the only drug that has been specifically developed for the indication of CHE and got approval in multiple European countries, Canada, South Korea and Israel for the treatment of severe chronic hand eczema (CHE), refractory to treatment with potent topical corticosteroid. Besides all these treatment options, the market consists of various unmet needs including limited availability of appropriate therapeutic treatment, poor understanding of disease in chronic state and lack of awareness.

To counter the current unmet needs, the market is expected to have better treatment options for CHE. With the continuous efforts in research and development, few companies are developing therapies such as LEO Pharma, Japan Tobacco, Asana Biosciences, Afecta Therapeutics, NUVO research and Aralez Pharmaceuticals. Detailed chapter for upcoming therapies like Delgocitinib (LEO Pharma); ASN002 (Asana Biosciences) have also been covered in the report

Chronic Hand Eczema Market Outlook

The Chronic Hand Eczema market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight

According to this research, the market of Chronic Hand Eczema in 7MM was found to be USD 1,226.71 million in 2017

Chronic Hand Eczema Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions

Chronic Hand Eczema Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Chronic Hand Eczema Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Chronic Hand Eczema Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Chronic Hand Eczema market
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Hand Eczema market
  • To understand the future market competition in the Chronic Hand Eczema market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Asana BioSciences
  • Basilea Pharmaceuticals
  • LEO Pharma
  • MORE
1. Key Insights

2. Chronic Hand Eczema: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Chronic Hand Eczema in 2017
2.2. Total Market Share (%) Distribution of Chronic Hand Eczema in 2028

3. Chronic Hand Eczema: Disease Background and Overview
3.1. Introduction
3.2. Classification
3.3. Etiology
3.4. Symptoms
3.5. Risk Factors
3.6. Pathogenesis
3.7. Defining CHE Severity & Therapeutic Response
3.8. Diagnosis
3.9. Differential diagnosis
3.10. Guidelines for Diagnosis of hand eczema - European Society of Contact Dermatitis (ESCD)
3.11. Diagnostic Algorithm

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Cases of Chronic Hand Eczema in 7MM
4.3. United States Epidemiology
4.3.1. Assumptions and Rationale
4.3.2. Total Prevalent Cases of Chronic Hand Eczema in the United States
4.3.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in the United States
4.3.4. Diagnosed Cases of Chronic Hand Eczema in the United States
4.3.5. Severity Specific Diagnosed Prevalent Cases of CHE in the United States
4.3.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in the United States
4.3.7. Age Specific Diagnosed Prevalent Cases of CHE in the United States
4.4. EU5 Epidemiology
4.5. Germany Epidemiology
4.5.1. Assumptions and Rationale
4.5.2. Total Prevalent Cases of Chronic Hand Eczema in Germany
4.5.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in Germany
4.5.4. Diagnosed Cases of Chronic Hand Eczema in Germany
4.5.5. Severity Specific Diagnosed Prevalent Cases of CHE in Germany
4.5.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in Germany
4.5.7. Age Specific Diagnosed Prevalent Cases of CHE in Germany
4.6. France Epidemiology
4.6.1. Assumptions and rationale
4.6.2. Total Prevalent Cases of Chronic Hand Eczema in France
4.6.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in France
4.6.4. Diagnosed Cases of Chronic Hand Eczema in France
4.6.5. Severity Specific Diagnosed Prevalent Cases of CHE in France
4.6.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in France
4.6.7. Age-Specific Diagnosed Prevalent Cases of CHE in France
4.7. Italy Epidemiology
4.7.1. Assumptions and Rationale
4.7.2. Total Prevalent Cases of Chronic Hand Eczema in Italy
4.7.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in Italy
4.7.4. Diagnosed Cases of Chronic Hand Eczema in Italy
4.7.5. Severity Specific Diagnosed Prevalent Cases of CHE in Italy
4.7.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in Italy
4.7.7. Age Specific Diagnosed Prevalent Cases of CHE in Italy
4.8. Spain Epidemiology
4.8.1. Assumptions and Rationale
4.8.2. Total Prevalent Cases of Chronic Hand Eczema in Spain
4.8.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in Spain
4.8.4. Diagnosed Cases of Chronic Hand Eczema in Spain
4.8.5. Severity Specific Diagnosed Prevalent Cases of CHE in Spain
4.8.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in Spain
4.8.7. Age-Specific Diagnosed Prevalent Cases of CHE in Spain
4.9. United Kingdom Epidemiology
4.9.1. Assumptions and Rationale
4.9.2. Total Prevalent Cases of Chronic Hand Eczema in the UK
4.9.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in UK
4.9.4. Diagnosed Cases of Chronic Hand Eczema in the UK
4.9.5. Severity Specific Diagnosed Prevalent Cases of CHE in the UK
4.9.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in the UK
4.9.7. Age Specific Diagnosed Prevalent Cases of CHE in the UK
4.10. Japan Epidemiology
4.10.1. Assumptions and Rationale
4.10.2. Total Prevalent Cases of Chronic Hand Eczema in Japan
4.10.3. Gender Specific Prevalent Cases of Chronic Hand Eczema in Japan
4.10.4. Diagnosed Cases of Chronic Hand Eczema in Japan
4.10.5. Severity Specific Diagnosed Prevalent Cases of CHE in Japan
4.10.6. Subgroup-Specific Diagnosed Prevalent Cases of CHE in Japan
4.10.7. Age Specific Diagnosed Prevalent Cases of CHE in Japan

5. Prevention and Treatment of Chronic Hand Eczema
5.1. Prevention
5.2. Treatment
5.3. Consensus statement for the management of chronic hand eczema - British Association of Dermatologists
5.4. Prevention and Treatment of hand eczema - European Society of Contact Dermatitis (ESCD) guidelines
5.5. Treatment algorithm for Chronic Hand Eczema

6. Unmet Needs

7. Marketed Drugs
7.1. Toctino: Basilea Pharmaceutica/ Stiefel Laboratories
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Other Development Activities
7.1.4. Safety and Efficacy
7.1.5. Product Profile

8. Emerging Therapies

9. Key Cross Competition
9.1. Delgocitinib: LEO Pharma/ Japan Tobacco
9.1.1. Product Description
9.1.2. Other Developmental Activities
9.1.3. Clinical Development
9.1.4. Safety and Efficacy
9.1.5. Product Profile
9.2. ASN002: Asana Biosciences
9.2.1. Drug Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile

10. Chronic Hand Eczema: 7MM Market Analysis
10.1. Key Findings
10.2. Market Size of Chronic Hand Eczema in 7MM
10.3. United States: Market Outlook
10.3.1. United States Market Size
10.3.2. Total Market size of Chronic Hand Eczema
10.3.3. Market Size of Chronic Hand Eczema by Therapies in the US
10.4. EU-5 countries: Market Outlook
10.5. Germany Market Size
10.5.1. Total Market size of Chronic Hand Eczema
10.5.2. Market Size of Chronic Hand Eczema by Therapies in Germany
10.6. France Market Size
10.6.1. Total Market size of Chronic Hand Eczema
10.6.2. Market Size of Chronic Hand Eczema by Therapies in France
10.7. Italy Market Size
10.7.1. Total Market size of Chronic Hand Eczema
10.7.2. Market Size of Chronic Hand Eczema by Therapies in Italy
10.8. Spain Market Size
10.8.1. Total Market size of Chronic Hand Eczema
10.8.2. Market Size of Chronic Hand Eczema by Therapies in Spain
10.9. United Kingdom Market Size
10.9.1. Total Market size of Chronic Hand Eczema
10.9.2. Market Size of Chronic Hand Eczema by Therapies in the UK
10.10. Japan Market Outlook
10.10.1. Japan Market Size
10.10.2. Total Market size of Chronic Hand Eczema
10.10.3. Market Size of Chronic Hand Eczema by Therapies in Japan

11. Market Drivers

12. Market Barriers

13. Appendix
13.1. Report Methodology

14. Publisher Capabilities

15. Disclaimer

16. About the Publisher

List of Tables
Table 1: Classification of Hand Eczema
Table 2: Definition of subtypes of hand eczema
Table 3: Etiological classification of Hand Eczema
Table 4: Morphological classification of Hand Eczema
Table 5: Characteristics for the various sub diagnostic groups
Table 6: Subgroups of hand eczema and definitions
Table 7: Risk factors for development of HE
Table 8: Physician’s global assessment for chronic hand eczema
Table 9: Modified total lesion symptom score
Table 10: Scoring of the patch test according to ICDRG recommendations
Table 11: Diagnostic Evaluation of Hand Eczema
Table 12: Signs and symptoms of superficially similar lesions of the hand eczema
Table 13: Recommendations for the Classification and diagnosis of Hand Eczema
Table 14: Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017-2028)
Table 15: Total Prevalent Cases of Chronic Hand Eczema in the US (2017-2028)
Table 16: Gender-Specific Prevalent Cases of CHE in the US (2017-2028)
Table 17: Diagnosed Cases of Chronic Hand Eczema in the US (2017-2028)
Table 18: Severity Specific Diagnosed Prevalent Cases of CHE in the US (2017-2028)
Table 19: Subgroup Specific Diagnosed Prevalent Cases of CHE in the US (2017-2028)
Table 20: Age-Specific Diagnosed Prevalent Cases of CHE in the US (2017-2028)
Table 21: Total Prevalent Cases of Chronic Hand Eczema in Germany (2017-2028)
Table 22: Gender-Specific Prevalent Cases of CHE in Germany (2017-2028)
Table 23: Diagnosed Cases of Chronic Hand Eczema in Germany (2017-2028)
Table 24: Severity Specific Diagnosed Prevalent Cases of CHE in Germany (2017-2028)
Table 25: Subgroup Specific Diagnosed Prevalent Cases of CHE in Germany (2017-2028)
Table 26: Age-Specific Diagnosed Prevalent Cases of CHE in Germany (2017-2028)
Table 27: Total Prevalent Cases of Chronic Hand Eczema in France (2017-2028)
Table 28: Gender-Specific Prevalent Cases of CHE in France (2017-2028)
Table 29: Diagnosed Cases of Chronic Hand Eczema in France (2017-2028)
Table 30: Severity Specific Diagnosed Prevalent Cases of CHE in France (2017-2028)
Table 31: Subgroup Specific Diagnosed Prevalent Cases of CHE in France (2017-2028)
Table 32: Age-Specific Diagnosed Prevalent Cases of CHE in France (2017-2028)
Table 33: Total Prevalent Cases of Chronic Hand Eczema in Italy (2017-2028)
Table 34: Gender-Specific Prevalent Cases of CHE in Italy (2017-2028)
Table 35: Diagnosed Cases of Chronic Hand Eczema in Italy (2017-2028)
Table 36: Severity Specific Diagnosed Prevalent Cases of CHE in Italy (2017-2028)
Table 37: Subgroup Specific Diagnosed Prevalent Cases of CHE in Italy (2017-2028)
Table 38: Age-Specific Diagnosed Prevalent Cases of CHE in Italy (2017-2028)
Table 39: Total Prevalent Cases of Chronic Hand Eczema in Spain (2017-2028)
Table 40: Gender-Specific Prevalent Cases of CHE in Spain (2017-2028)
Table 41: Diagnosed Cases of Chronic Hand Eczema in Spain (2017-2028)
Table 42: Severity Specific Diagnosed Prevalent Cases of CHE in Spain (2017-2028)
Table 43: Subgroup Specific Diagnosed Prevalent Cases of CHE in Spain (2017-2028)
Table 44: Age-Specific Diagnosed Prevalent Cases of CHE in Spain (2017-2028)
Table 45: Total Prevalent Cases of Chronic Hand Eczema in the UK (2017-2028)
Table 46: Gender-Specific Prevalent Cases of CHE in the UK (2017-2028)
Table 47: Diagnosed Cases of Chronic Hand Eczema in the UK (2017-2028)
Table 48: Severity Specific Diagnosed Prevalent Cases of CHE in the UK (2017-2028)
Table 49: Subgroup Specific Diagnosed Prevalent Cases of CHE in the UK (2017-2028)
Table 50: Age-Specific Diagnosed Prevalent Cases of CHE in the UK (2017-2028)
Table 51: Total Prevalent Cases of Chronic Hand Eczema in Japan (2017-2028)
Table 52: Gender-Specific Prevalent Cases of CHE in Japan (2017-2028)
Table 53: Diagnosed Cases of Chronic Hand Eczema in Japan (2017-2028)
Table 54: Severity Specific Diagnosed Prevalent Cases of CHE in Japan (2017-2028)
Table 55: Subgroup Specific Diagnosed Prevalent Cases of CHE in Japan (2017-2028)
Table 56: Age-Specific Diagnosed Prevalent Cases of CHE in Japan (2017-2028)
Table 57: Skin protection program based on evidence from clinical and experimental studies
Table 58: Treatment options for chronic HE
Table 59: Recommendations for the Prevention of Hand Eczema
Table 60: Recommendations for the Treatment of Hand Eczema
Table 61: Recommendations for the Systemic treatment of Chronic Hand Eczema
Table 62: Key Cross: Emerging Therapies
Table 63: Delgocitinib, Clinical Trial Description, 2019
Table 64: ASN002, Clinical Trial Description, 2019
Table 65: Market Size of Chronic Hand Eczema in 7MM in USD Million (2017-2028)
Table 66: The US Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 67: Market Size of CHE by therapies in the US in USD Million (2017-2028)
Table 68: Germany Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 69: Market Size of CHE by therapies in Germany in USD Million (2017-2028)
Table 70: France Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 71: Market Size of CHE by therapies in France in USD Million (2017-2028)
Table 72: Italy Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 73: Market Size of CHE by therapies in Italy in USD Million (2017-2028)
Table 74: Spain Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 75: Market Size of CHE by therapies in Spain in USD Million (2017-2028)
Table 76: UK Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 77: Market Size of CHE by therapies in the UK in USD Million (2017-2028)
Table 78: Japan Market Size of Chronic Hand Eczema in USD Million (2017-2028)
Table 79: Market Size of CHE by therapies in Japan in USD Million (2017-2028)

List of Figures
Figure 1: Establish diagnosis of acute hand dermatitis and chronic hand dermatitis (CHD)
Figure 2: Skin immune system
Figure 3: Photographic severity guide used in physician’s global assessment scoring
Figure 4: Flow chart for diagnosis of HE
Figure 5: Diagnostic chronic hand eczema (CHE) algorithm
Figure 6: Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017-2028)
Figure 7: Total Prevalent cases of Chronic Hand Eczema in the US (2017-2028)
Figure 8: Gender Specific Prevalent cases of CHE in the US (2017-2028)
Figure 9: Diagnosed Cases of Chronic Hand Eczema in the US (2017-2028)
Figure 10: Severity Specific Diagnosed Prevalent Cases of CHE in the US (2017-2028)
Figure 11: Subgroup Specific Diagnosed Prevalent Cases of CHE in the US (2017-2028)
Figure 12: Age-Specific Diagnosed Prevalent Cases of CHE in the US (2017-2028)
Figure 13: Total Prevalent cases of Chronic Hand Eczema in Germany (2017-2028)
Figure 14: Gender Specific Prevalent cases of CHE in Germany (2017-2028)
Figure 15: Diagnosed Cases of Chronic Hand Eczema in Germany (2017-2028)
Figure 16: Severity Specific Diagnosed Prevalent Cases of CHE in Germany (2017-2028)
Figure 17: Subgroup Specific Diagnosed Prevalent Cases of CHE in Germany (2017-2028)
Figure 18: Age-Specific Diagnosed Prevalent Cases of CHE in Germany (2017-2028)
Figure 19: Total Prevalent cases of Chronic Hand Eczema in France (2017-2028)
Figure 20: Gender Specific Prevalent cases of CHE in France (2017-2028)
Figure 21: Diagnosed Cases of Chronic Hand Eczema in France (2017-2028)
Figure 22: Severity Specific Diagnosed Prevalent Cases of CHE in France (2017-2028)
Figure 23: Subgroup Specific Diagnosed Prevalent Cases of CHE in France (2017-2028)
Figure 24: Age-Specific Diagnosed Prevalent Cases of CHE in France (2017-2028)
Figure 25: Total Prevalent cases of Chronic Hand Eczema in Italy (2017-2028)
Figure 26: Gender Specific Prevalent cases of CHE in Italy (2017-2028)
Figure 27: Diagnosed Cases of Chronic Hand Eczema in Italy(2017-2028)
Figure 28: Severity Specific Diagnosed Prevalent Cases of CHE in Italy (2017-2028)
Figure 29: Subgroup Specific Diagnosed Prevalent Cases of CHE in Italy (2017-2028)
Figure 30: Age-Specific Diagnosed Prevalent Cases of CHE in Italy (2017-2028)
Figure 31: Total Prevalent cases of Chronic Hand Eczema in Spain (2017-2028)
Figure 32: Gender Specific Prevalent cases of CHE in Spain (2017-2028)
Figure 33: Diagnosed Cases of Chronic Hand Eczema in Spain (2017-2028)
Figure 34: Severity Specific Diagnosed Prevalent Cases of CHE in Spain (2017-2028)
Figure 35: Subgroup Specific Diagnosed Prevalent Cases of CHE in Spain (2017-2028)
Figure 36: Age-Specific Diagnosed Prevalent Cases of CHE in Spain (2017-2028)
Figure 37: Total Prevalent cases of Chronic Hand Eczema in the UK (2017-2028)
Figure 38: Gender Specific Prevalent cases of CHE in the UK (2017-2028)
Figure 39: Diagnosed Cases of Chronic Hand Eczema in the UK (2017-2028)
Figure 40: Severity Specific Diagnosed Prevalent Cases of CHE in the UK (2017-2028)
Figure 41: Subgroup Specific Diagnosed Prevalent Cases of CHE in the UK (2017-2028)
Figure 42: Age-Specific Diagnosed Prevalent Cases of CHE in the UK (2017-2028)
Figure 43: Total Prevalent cases of Chronic Hand Eczema in Japan (2017-2028)
Figure 44: Gender Specific Prevalent cases of CHE in Japan (2017-2028)
Figure 45: Diagnosed Cases of Chronic Hand Eczema in Japan (2017-2028)
Figure 46: Severity Specific Diagnosed Prevalent Cases of CHE in Japan (2017-2028)
Figure 47: Subgroup Specific Diagnosed Prevalent Cases of CHE in Japan (2017-2028)
Figure 48: Age-Specific Diagnosed Prevalent Cases of CHE in Japan (2017-2028)
Figure 49 General Principles for the treatment of hand eczema
Figure 50: Treatment algorithm for hand eczema
Figure 51: Treatment algorithm for chronic hand eczema (CHE)
Figure 52: Unmet Needs of Chronic Hand Eczema
Figure 53: Market Size of Chronic Hand Eczema in 7MM in USD Million (2017-2028)
Figure 54: Market Size of Chronic Hand Eczema in the US, USD Millions (2017-2028)
Figure 55: Market Size of CHE by therapies in the US in USD Million (2017-2028)
Figure 56: Market Size of Chronic Hand Eczema in Germany, USD Millions (2017-2028)
Figure 57: Market Size of CHE by therapies in Germany in USD Million (2017-2028)
Figure 58: Market Size of Chronic Hand Eczema in France, USD Millions (2017-2028)
Figure 59: Market Size of CHE by therapies in France in USD Million (2017-2028)
Figure 60: Market Size of Chronic Hand Eczema in Italy, USD Millions (2017-2028)
Figure 61: Market Size of CHE by therapies in Italy in USD Million (2017-2028)
Figure 62: Market Size of Chronic Hand Eczema in Spain, USD Millions (2017-2028)
Figure 63: Market Size of CHE by therapies in Spain in USD Million (2017-2028)
Figure 64: Market Size of Chronic Hand Eczema in UK, USD Millions (2017-2028)
Figure 65: Market Size of CHE by therapies in the UK in USD Million (2017-2028)
Figure 66: Market Size of Chronic Hand Eczema in Japan, USD Millions (2017-2028)
Figure 67: Market Size of CHE by therapies in Japan in USD Million (2017-2028)
Figure 68: Market Drivers
Figure 69:Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Basilea Pharmaceuticals
  • LEO Pharma
  • Asana BioSciences
Note: Product cover images may vary from those shown
Adroll
adroll